These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 8369164

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.
    Groenink M, Moore JP, Broersen S, Schuitemaker H.
    J Virol; 1995 Jan; 69(1):523-7. PubMed ID: 7983749
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.
    Moore JP, McKeating JA, Huang YX, Ashkenazi A, Ho DD.
    J Virol; 1992 Jan; 66(1):235-43. PubMed ID: 1727487
    [Abstract] [Full Text] [Related]

  • 10. Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.
    Beaumont T, Quakkelaar E, van Nuenen A, Pantophlet R, Schuitemaker H.
    J Virol; 2004 Jun; 78(11):5651-7. PubMed ID: 15140962
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies.
    Potts BJ, Field KG, Wu Y, Posner M, Cavacini L, White-Scharf M.
    Virology; 1993 Nov; 197(1):415-9. PubMed ID: 8212576
    [Abstract] [Full Text] [Related]

  • 16. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ, McKeating JA, Schutten M, Reitz MS, Robert-Guroff M.
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [Abstract] [Full Text] [Related]

  • 17. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells.
    Moore JP, Sattentau QJ, Klasse PJ, Burkly LC.
    J Virol; 1992 Aug; 66(8):4784-93. PubMed ID: 1378510
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.
    Mori T, Boyd MR.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):664-72. PubMed ID: 11181340
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.